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Abstract
Quantitative enzyme accessibility experiments using nano liquid chromatography electrospray mass spectrometry combined with limited
proteolysis and isotope-labeling was used to examine the dynamic nature of the human rhinovirus (HRV) capsid in the presence of three
antiviral compounds, a neutralizing Fab, and drug binding cavity mutations. Using these methods, it was found that the antivirals WIN 52084
and picovir (pleconaril) stabilized the capsid, while dansylaziridine caused destabilization. Site-directed mutations in the drug-binding cavity
were found to stabilize the HRV14 capsid against proteolytic digestion in a manner similar to WIN 52084 and pleconaril. Antibodies that
bind to the NIm-IA antigenic site and penetrate the canyon were also observed to protect the virion against proteolytic cleavage. These
results demonstrate that quantifying the effects of antiviral ligands on protein “breathing” can be used to compare their mode of action and
efficacy. In this case, it is apparent that hydrophobic antiviral agents, antibodies, or mutations in the canyon region block viral breathing.
Therefore, these studies demonstrate that mobility in the canyon region is a major determinant in capsid breathing.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
Picornaviruses are among the largest of animal virus
families and include polio, hepatitis A, foot-and-mouth dis-
ease, and rhinoviruses. Rhinoviruses, of which there are
more than 100 serotypes, are major causative agents of the
common cold in humans (Rueckert, 1996). Human rhino-
virus infections begin with binding of the virion to their
receptor on the outside of the cell, translocation of the virus
particles into the cell, and the release of its genomic material
into the cytoplasm. The virus particle must be flexible
enough to allow cellular binding and disassembly of the
virions yet stable enough to survive in the extracellular
milieu. In fact, several reports have shown that the viral
capsid is a dynamic structure that transiently exposes deeply
buried N-termini (Fricks and Hogle, 1990; Lewis et al.,
1998; Li et al., 1994).
The human rhinovirus is nonenveloped and has an
300-Å-diameter protein shell that encapsidates a single-
stranded, plus-sense, RNA genome of about 7200 bases.
The human rhinovirus 14 (HRV14) capsid exhibits a pseudo
T  3 (P  3) icosahedral symmetry and consists of 60
copies each of four viral proteins, VP1, VP2, VP3, and VP4.
Proteins VP1-3 have eight-stranded, antiparallel -barrel
motifs and comprise most of the capsid structure. VP4 is
smaller, has an extended structure, and lies at the RNA/
capsid interface, making it the most interior capsid protein
(Rossmann et al., 1985). An 20-Å-deep canyon lies
roughly at the junction of VP1 (forming the “north” rim)
with VP2 and VP3 (forming the “south” rim) and surrounds
each of the 12 icosahedral fivefold vertices (Fig. 1). Four
major neutralizing immunogenic (NIm) sites, NIm-IA,
NIm-IB, NIm-II, and NIm-III, were identified by studies of
neutralization-escape mutants with monoclonal antibodies
(Sherry et al., 1986; Sherry and Rueckert, 1985) and
mapped to four protruding regions on the viral surface
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(Rossmann et al., 1985). The canyon regions of HRV14 and
HRV16, both major receptor group rhinoviruses, contain the
binding site of the cellular receptor, intercellular adhesion
molecule 1 (ICAM-1) (Colonno et al., 1988; Kolatkar et al.,
1999; Olson et al., 1993).
X-ray crystallographic studies have shown that antiviral
compounds (WIN drugs) that inhibit uncoating bind to a
hydrophobic pocket immediately beneath the floor of the
canyon (Smith et al., 1986) (Fig. 1). While these structural
studies have yielded a wealth of information as to drug–
virus interactions, they do not elucidate the conformational
changes associated with the uncoating process. Modern
mass spectrometry techniques such as matrix-assisted laser
desorption/ionization (MALDI) and electrospray ionization
(ESI), combined with limited proteolysis, have been used to
monitor the dynamic nature of virus particles (Bothner et
Fig. 1. Structures of WIN drugs and Fab17-IA bound to HRV14. Shown in the top left figure is a ribbon diagram of one protomer of HRV14 complexed
with WIN 52084 (Smith et al., 1986). VP1–VP4 are colored blue, green, red, and mauve, respectively. In this view, the RNA interior is toward the bottom
of the figure and the nearest five-fold axis runs approximately vertical on the left side. WIN 52084 is represented by a space-filling model beneath the canyon
region. In the upper right diagram is a ribbon diagram of the Fab17-IA/HRV14 complex (Smith et al., 1996) in approximately the same orientation. Here
the variable regions of the heavy and light chains of Fab17-IA are shown in yellow and white, respectively. The bottom panel is a stereo diagram of the WIN
52084/HRV14 complex with the V1188M and C1199W mutations modeled to show how they fill the drug binding cavity and sterically block WIN binding.
For clarity, the view is rotated 180° about the vertical axis compared to the top panels. For this figure, the drug and associated conformational changes were
taken from the WIN 52084 structure (Smith et al., 1986). The C1199W mutation was modeled by replacing residues 1196–1201 of the WIN/HRV14 complex
with those of the structure of the C1199Y mutant (Badger et al., 1989) and then replacing the TYR with a TRP using the graphics program “O” (Kleywegt
and Jones, 1994). The V1188M mutation was modeled using “O” to replace the VAL with a MET and orienting the side chain in the most favored rotomer
position. The original structures about these residues are shown in white in the figure.
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al., 1999). More specifically, viral capsid mass mapping
experiments have been used to obtain information regarding
the dynamic nature of the viral capsid in the presence of
antiviral compounds (Lewis et al., 1998). In these experi-
ments, peptide fragments from limited proteolysis can be
identified by MALDI-MS, thereby elucidating the relative
accessibility of protein regions. Such experiments have
shown that the HRV14 capsid transiently extrudes internal
VP1 and VP4 N-termini in a “breathing” process (Lewis et
al., 1998). Since this dynamic process is affected by a
number of antiviral compounds, this technique is proving
especially useful in the evaluation of such drugs in a rapid,
mass-spectrometry-based manner without the complications
of cell toxicity.
While the original WIN compounds tended to have rel-
atively narrow serotype specificity, a derivative of these
compounds, picovir (pleconaril), has demonstrated even
greater efficacy for treatment of a range of rhinovirus sero-
types and is currently in clinical trials (Kaiser et al., 2000).
Pleconaril and other similar isoxazole analogs bind to the
VP1 pockets primarily through hydrophobic interactions
with residues beneath the canyon floor. This results in sta-
bilization of the virus particle that prevents the capsid from
uncoating and the RNA from entering cells (Romero, 2001).
In contrast to the non-covalent binding of pleconaril, aziri-
dine compounds have recently been shown to block virus
infectivity by covalently modifying the bases on the viral
RNA or DNA of various types of viruses (Broo et al., 2001).
In a manner similar to the replacement of wild-type flock
house virus RNA with cellular RNA (Bothner et al., 1999),
the aziridine-alkylated nucleotide bases destabilize the
RNA–protein contacts and therefore the entire viral capsid
structure. Due to their high reactivity and lack of selectivity,
these alkylating agents are currently under investigation for
their potential in the development of antiviral vaccine prep-
arations (Burrage et al., 2000a,b). While the targets (i.e.,
RNA versus protein) are different for these two types of
antiviral agents, both rely upon the flexibility of the protein
capsid to neutralize infectivity.
Here we further examine and quantify the breathing
phenomena in HRV14. Limited proteolysis experiments us-
ing serine proteases were employed to monitor the effects of
WIN 52084, pleconaril, and dansylaziridine on the viral
protein capsid with and without O18 labeling. By analyzing
the virus digestions with several mass spectrometry (MS)
techniques including capillary nano liquid chromatography)
LC-MS and MALDI mass spectrometry, we demonstrate
that WIN 52084 and pleconaril decrease HRV14 dynamics,
while an aziridine derivative causes an increase. It was
previously suggested that the binding of hydrophobic com-
pounds to the drug-binding pocket causes stabilization by a
change in entropy (Phelps and Post, 1995; Smith, 1989;
Tsang et al., 2000). This is supported here by the demon-
stration that filling the drug-binding pocket with hydropho-
bic side chains decreases capsid breathing in a manner
similar to the WIN compounds. It has also been suggested
that motion in the canyon might be the dynamic process
being affected by these drugs (Lewis et al., 1998). This
contention is supported by results presented here showing
that Fab17, that penetrates the canyon region, does not
induce conformational changes in the virion and yet also
inhibits virus breathing. Together, these results imply that
movement of the canyon region is a prerequisite for breath-
ing. Further, since viral breathing is correlated with infec-
tivity, it also suggests that canyon motion is essential for the
normal uncoating process.
Results
Fab17 effects on HRV14 breathing
Antibodies are a major component of the immune re-
sponse to rhinovirus infection. There are four immunogenic
regions (NIm sites) on the HRV14 surface: NIm-IA, NIm-
IB, NIm-II, and NIm-III. The major mechanism of anti-
body-mediated neutralization for antibodies to all of these
antigenic sites appears to be abrogation of cell attachment
(Che et al., 1998; Smith et al., 1993). However, antibodies
to the NIm-IA site appear to also stabilize the virion (Che et
al., 1998). This was proposed to be due to these antibodies
binding in the canyon region (Fig. 1) that is involved in the
conformational changes associated with the uncoating pro-
cess. HRV14 complexed with the neutralizing Fab frag-
ment. Fab17-IA, resisted enzymatic degradation on the pro-
tein capsid as evidenced by MALDI-TOF mass analysis of
digests on intact viruses. Even at a pH of 4.3, below the pH
required to inactivate the virus, Glu-C enzymatic digestion
of the virus particles was inhibited by the presence of HRV
NIm-1A antibodies (Fig. 2). These effects cannot be due to
Fab17 sterically interfering with the protease accessing the
cleavage sites since, as we have previously shown, the
initial and major protease cleavage sites are buried deep
within the capsid (Lewis et al., 1998) and are therefore not
Fig. 2. Limited proteolysis of HRV14 in the presence or absence of FAb.
MALDI-TOF spectra from a 15-min limited proteolysis of HRV14 in the
presence (B) and absence (A) of Fab17. Note that Fab17 greatly inhibits
proteolysis even at this low pH (10 mM ammonium acetate, pH 4.3).
Spectra were set to the same relative scale.
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in contact with the bound Fab17. Therefore, the fact that the
internal protease sites on the VP1 and VP4 termini are
protected by Fab17 is consistent with the global stabilizing
effects of this class of antibodies. Further, this suggests that
the antibody-mediated stabilization coincides with a de-
crease in capsid mobility.
Effects of ligands on HRV14 breathing
The WIN class of antiviral drugs has been shown to have
a general stabilizing effect on the viral capsid in addition to
reducing cell attachment and inhibiting the uncoating pro-
cess (Lewis et al., 1998). Our current results confirm these
data; WIN 52084 decreased proteolysis of HRV14 as seen
by the reduced amount of peptide fragments during a 1 h
digestion with trypsin (Fig. 3A). Peptides were confirmed to
have resulted from proteolysis of HRV14 as previously
described (Lewis et al., 1998). There are no proteolytic
fragments in wild-type prior to digestion. WIN 52084 has
previously been shown to decrease the accessibility of tryp-
sin to cleavage sites on the viral coat rather than inhibiting
the enzymatic activity of trypsin itself (Lewis et al., 1998).
It is apparent from these and other experiments that the
WIN drug not only affects local conformation but also has
a global stabilizing effect.
When HRV14 is grown in the presence of high concen-
trations of WIN drugs, naturally occurring mutants at two
residues are commonly selected for V1188 and C1199
(Heinz et al., 1989). These mutations reside in the pocket
region where the WIN drug normally binds and render the
pocket inaccessible. This has been shown both crystallo-
graphically (Heinz et al., 1989) and through binding studies
that these compounds do not bind to the V1188 mutations
and that there is a direct correlation between drug efficacy
and affinity (Fox et al., 1991). In the case of the C1199Y,
filling the cavity with a more hydrophobic residue stabilizes
the virion against thermal denaturation (Shepard et al.,
1993). To ascertain whether thermal denaturation of
HRV14 is related to the breathing phenomenon, and if
filling the pocket with hydrophobic residues blocks this
process, a double mutation of HRV14 was made, V1188M/
C1199W, and proteolytic sensitivity was measured. Similar
to the single mutant, this double mutant was found to be
more stable than wild-type, but less stable than wild-type 
Fig. 3. Limited proteolysis of HRV14 under various conditions. (A) MALDI-TOF spectra of HRV14 wild-type and C1199W/V1188M mutant in the presence
and absence of WIN compound. Spectra were set to the same relative scale. While wild-type virus is readily digested when exposed to trypsin for 1 h
(spectrum second from the top) compared to undigested HRV14 (top spectrum), both mutant and wild-type virus  WIN are resistant to proteolysis (bottom
spectrum). Asterisk (*) denotes the intact VP4 protein. (B) Time course of VP4 digestion of wild-type virus in the presence and absence of WIN and DA
compounds. Note that, compared to the wild-type control, WIN compounds protect VP4 while DA facilitates proteolysis. Graphs B and C were generated
from individual MALDI spectra, such as in Fig. 2A, using the peak height of VP4. For each treatment (Control, WIN, or DA), the VP4 peak at zero time
was set to 100% and the percentage of VP4 from the remaining time points were calculated based on this value. (C) Time course of the C1199W/V1188M
mutant form of HRV14 in the presence and absence of WIN and DA. WIN does not appear to significantly change the sensitivity of VP4 to cleavage compared
to the mutant control. In addition, while the mutant is more resistant to digestion than wild-type virus, it is less sensitive than wild-type virusWIN. Similar
to wild-type virus, DA increases sensitivity of VP4.
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WIN (data not shown). Furthermore, the double mutant was
not further stabilized by the addition of WIN compound and
is consistent with the assumption that the drug did not bind
to this double mutant. With regard to plaque size and viral
yield, this particular mutant exhibits a wild-type phenotype.
As shown in Fig. 3A, this double mutation dramatically
reduced proteolysis when compared to wild-type HRV14.
In the absence of WIN 52084, the mutant viral coat under-
goes proteolysis in a manner similar to wild-type virus in
the presence of WIN 52084. DMSO, the solvent used for
WIN, alone had no apparent effect on proteolysis of HRV14
or the V1188M/C1199W mutant. These results strongly
suggest that thermal denaturation of HRV14 is directly
related to breathing and that the drugs stop this dynamic
process through entropic effects.
By measuring the degradation of VP4 over increasing
digestion times, we can also compare the long-term stabi-
lization effects conferred by the WIN compounds and the
mutations. Because the levels of VP4 consistently decreased
as the proteolytic fragments increased, it proved useful to
compare digestion of wild-type virus to the mutant virus
using VP4 intensities. It should be noted that the graphs
presented are only semiquantitative and are used to express
the trend in proteolysis. As shown in Fig. 3B and C, VP4
from wild-type virus is almost completely digested within
1 h in the absence of WIN but is present after 18 h in the
presence of WIN. By contrast, although the mutant is some-
what affected by WIN, there is a significant amount of VP4
present after 1 h (also see Fig. 2A, bottom spectrum). In
addition, after 18 h VP4 is almost entirely digested in the
mutant, regardless whether or not WIN is present. This is in
contrast to what is observed in wild-type virus, where WIN
causes a much more dramatic effect. Digestions performed
for 24 h resulted in no apparent differences in VP4 levels
when compared to 18 h (data not shown). From this anal-
ysis, it is clear that the V1188M/C1199W mutant is more
stable than wild-type virus but not as stable as wild-type
virus plus WIN compounds. As expected, the stability of the
mutant virus is less affected by the presence of WIN com-
pounds than wild-type. These results are consistent with
infectivity studies (U. Katpally and T. J. Smith, unpublished
data). Since these mutations all fill the drug cavity with
hydrophobic side chains, these results support the conten-
tion that WIN compounds act via entropic stabilization
(Phelps and Post, 1995; Smith, 1989; Tsang et al., 2000).
In contrast to pleconaril, dansylaziridine (DA) acts by
using the dynamic nature of the capsid to penetrate the
virion and modify the RNA genome, resulting in a destabi-
lization of the capsid (Broo et al., 2001). This phenomena is
also observed in the current experiments (Figs. 3B and C).
In the presence of DA, VP4 of wild-type virus is cleaved in
less than 10 min. Similarly, DA sensitizes VP4 cleavage in
the mutant, but to a slightly lesser extent than that observed
with wild-type virus. In the presence of the solvent for DA,
acetonitrile, alone, digestion of the HRV14, and the
V1188M/C1199W mutant are comparable to controls.
Effects of pleconaril
Similar to WIN compounds and Fab17-IA, incubation of
HRV with pleconaril under physiologically relevant condi-
tions (i.e., 37°C, pH 7.5) yielded significantly fewer peptide
products than HRV solutions absent of pleconaril (Fig. 4).
Figs. 4A and B show the MALDI spectra from 15-min
tryptic digestions following a 1 h incubation with pleconaril
(Fig. 4B) and an incubation absent of the drug (Fig. 4A).
The presence of pleconaril inhibited digestion as ascertained
by the reduced amount of peptide fragments. Additional
analysis of aliquots from longer digestion times continued
to demonstrate this trend (data not shown).
The hydrophobic character of pleconaril and its analogs
contribute to its selective and high-affinity binding in the
VP1 pocket, but also limits its solubility in aqueous solu-
tions. Acetonitrile at a concentration of more than 75% (v/v)
was required to dissolve 2 mg pleconaril per milliliter of
solution. Serial dilutions minimized the organic solvent
content (less than 1% v/v) and the amount of drug was less
Fig. 4. MALDI-TOF spectra from a 30-min limited proteolysis of HRV-14
(A) alone, (B) after incubation with pleconaril, (C) in the presence of
-cyclodextrin, and (D) in the presence of -cyclodextrin and pleconaril.
All spectra are displayed on the same intensity scale. All incubations and
subsequent proteolytic digestions were performed on HRV at 1.0 mg/mL
and at 37°C. The concentration of pleconaril (at 112 mM) was six times the
concentration of cyclodextrin.
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than 50 M. However, delivering more drug to the virus
solution without additional organic solvent was investigated
as a possible means of further inhibiting the viral capsid
dynamics. Cyclodextrin has previously been used to en-
hance drug solubility by acting as a “cage” molecule (Ra-
jewski and Stella, 1996), and more specifically as a vehicle
for pirodavir, an antiviral with in vitro activity against
rhinoviruses (Hayden et al., 1992). As a simple test, -cy-
clodextrin was used to increase the amount of drug added to
the virus solution with only trace amounts (less than 0.2%
v/v) of organic solvent. With the addition of cyclodextrin at
a concentration of approximately six times less than the
concentration of pleconaril, the HRV proteins were further
protected from digestion (compare Fig. 4B with D). The
presence of cyclodextrin alone had no effect on HRV pro-
tease sensitivity (compare Fig. 4A with C). While it is
possible that cyclodextrin increases the solubility of some
peptides, and hence changes the mass spec profile slightly,
cyclodextrin itself does not decrease proteolysis. An even
further decrease in the proteolytic susceptibility is seen
when a larger amount of pleconaril was delivered to the
HRV solution (Fig. 4D) than without cyclodextrin (Fig.
4B). These results suggest that cyclodextrin is an efficacious
drug carrier system.
Drug mechanism of action
The qualitative results shown thus far demonstrate the
general stabilizing effect of pleconaril. However, to deter-
mine the relative effectiveness of this drug requires a more
quantitative approach. Nano-LC ion-trap mass spectrometry
is a particularly sensitive method for characterizing one or
more peptides in the midst of other constituents and is
appropriate for the quantitative analysis of peptide products
from proteolytic digestion of intact virions. Isotopically
labeled tryptic peptides were monitored by nano-LC-MS to
quantitatively show how pleconaril and dansylaziridine al-
tered the stability of the HRV. Incorporation of oxygen18
(O18) by enzyme-catalyzed hydrolysis has been an effective
means of quantitatively monitoring numerous substrates in-
cluding proteolytic peptides with several mass spectrometry
techniques (Desiderio and Kai, 1983; Kosaka et al., 2000;
Mirgorodskaya et al., 2000; Pickett and Murphy, 1981), and
more recently for comparative proteomics (Yao et al.,
2001). Peptide bonds hydrolyzed for short time periods in
the presence of O18–water incorporated an O18 atom into the
carboxy-terminus of the resulting peptides. This is visual-
ized as a peak that is apparent at two mass units above the
monoisotopic ion.
The O18-isotope labeling in this study was performed in
a manner that would not bias the results with respect to the
natural abundances of the MH (monoisotopic) and [MH
 2] isotopes. For biomolecules below 1000 D, the contri-
bution from monoisotopic ions dominates other isotopes
(Yergey et al., 1983); thus, an insignificant amount of
[MH  2] isotopes is typically observed in mass spectra of
small peptides. Controls for limited proteolysis experiments
were performed with samples where the aqueous solvent
was exchanged with O18–water, and in the absence of any
antiviral agents (Fig. 5A). Virus digestions containing an-
tiviral agents were performed in O16–water. Therefore,
when equal amounts of these digests were mixed, the effect
on the viral capsid would be noted in the relative abundance
of the monoisotopic peak relative to the O18-labeled peptide
(Figs. 5B and C). Considering the normally dominant abun-
dance of the monoisotopic peak for peptides in this mass
range, the relative intensity of this isotope in the presence of
these antiviral agents (in O16–water) establishes how each
antiviral agent affects the virus dynamics.
Since VP1 98–103 represents an externally exposed por-
tion of the capsid that was sensitive to proteolysis, it was
chosen as a clear marker for evaluating these drugs. This
relatively hydrophobic peptide is significant because it lies
in the canyon that is directly affected by the presence of
pleconaril. Although this peptide is only moderately acces-
sible to trypsin, it is observed in adequate, measurable
amounts in the presence or absence of antiviral compounds.
Proteolytic peptides other than VP1 displayed similar trends
for pleconaril and aziridine-treated HRV, but were observed
as multiply charged peaks, or nonstructurally relevant re-
gions of the virus (data not shown).
Control digests were conducted in O18–water in the ab-
sence of antiviral drugs. The control experiment shown in
Fig. 4A reveals that the digests performed in O18–water
with no drug present yields a dominant O18-labeled peak at
m/z 824 for the VP1 peptide. Since it is difficult to com-
pletely eliminate regular water from virus samples where
maintaining the virion structure is critical, virus digests
performed in O18–water were expected to show a small
contribution of monoisotopic peaks due to residual water
that remained. The typical amount of the unlabeled mo-
noisotopic species (m/z 822) observed was at 10–20% rel-
Fig. 5. Capillary LC-ESI mass spectrometric evaluation of isotopically
labeled peptides from a 15-min limited proteolysis of (A) HRV alone in
O18–water, (B) an equal mixture of HRV in the presence of pleconaril in
regular water and HRV alone in O18–water, and (C) an equal mixture of
HRV in the presence of dansylaziridine (DA) in regular water and HRV
alone in O18–water. Tryptic digests were quenched by the addition of acetic
acid and either loaded onto the capillary or frozen immediately for further
analyses.
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ative intensity to the labeled species (m/z 824) and was
primarily due to residual water left in the virus solution (Fig.
5A).
For experiments where pleconaril or dansylaziridine was
added, digests were performed in regular O16–water. Sub-
sequently, equal amounts of drug-positive digests (O16–
water) were mixed with control digests (O18–water). In this
situation, the effect on the viral capsid is apparent when the
relative abundance of the monoisotopic peak is compared to
the O18-labeled peptide. For example, if these experiments
were conducted using a drug that had no effect on the capsid
proteins, the result would be an equal abundance of peaks at
822 and 824 m/z (data not shown). The control digest (O18)
contributes the peak at 824 m/z and the peak at 822 m/z
comes from the experimental digest performed in regular
O16–water. If the drug had a suppressive effect, the peak at
822 m/z would be significantly lower than the peak at 824
m/z. As shown in Fig. 5A, the presence of pleconaril effec-
tively suppressed proteolytic digestion as exemplified by the
significantly lower abundance of the monoisotopic peak at
m/z 822 (40  11%) compared to the peak at 824 m/z
(100%). In the middle panel, O18–water from the control
digest presumably contributes much of the peak at m/z 822,
although there is likely to be limited digestion occurring in
the presence of pleconaril. This data support the hypothesis
that pleconaril acts by binding to the VP1 pockets and hence
stabilizing the protein capsid, making it less susceptible to
proteolysis.
In contrast to the effect of pleconaril, dansylaziridine
drastically increased the abundance of the VP1-derived pep-
tide at 822 m/z (Fig. 5C). As seen in the far right panel, the
822 m/z peak is significantly higher than the 824 m/z peak,
indicating that the presence of dansylaziridine effectively
increases tryptic digestion. The reactive dansylaziridine has
previously been shown to destabilize the virus particle by
disrupting the RNA/capsid protein interactions (Broo et al.,
2001). However, the global virus particle structure is not
compromised over the short term. Instead, the uncharged
aziridine molecules pass through the dynamically mobile
protein capsid to selectively alkylate the RNA rather than
break up the virus particle to expose the RNA for reaction.
Our current data support this hypothesis; the dynamic nature
of the protein capsid in the presence of dansylaziridine
allows for increased exposure to proteolytic digestion of the
capsid.
The results from this study illustrate the subtle changes
induced by the presence of antirhinovirus agents. While
these protein–protein and protein–RNA disruptions do not
compromise the structural integrity of the virus particles,
they significantly decrease HRV infectivity. HRV incubated
with the capsid-binding drug pleconaril and the alkylating
agents at 37°C each showed a threefold decrease in infec-
tivity, respectively (data not shown). No notable differences
were observed between untreated HRV and HRV treated
with dansylaziridine at 25°C. The increased capsid mobility
at the elevated temperature of 37°C presumably allowed the
dansylaziridine molecules to pass through the capsid to
alkylate the viral RNA. The temperature effect was less
pronounced for the capsid binding agent pleconaril, which
has a viral target near the virus capsid surface.
Discussion
These studies demonstrate that the dynamics of the viral
capsid is the “Achilles’ heel” of picornaviruses that can be
targeted by antivirals. Small quantities of pleconaril en-
hanced the stability of HRV, thereby decreasing the acces-
sibility of the protein capsid to enzymatic degradation. In
fact, pleconaril produced more than a 50% increase in sta-
bility compared to native virus as shown by proteolytic
accessibility and quantitative mass spectrometry (Fig. 5B).
WIN compounds have been shown to interfere with the
receptor/virus interactions of the major group of rhinovi-
ruses but not that of the minor group (Pevear et al., 1989).
ICAM-I is the receptor for the major group of rhinoviruses
and binds to the upper south wall of the canyon region
(Olson et al., 1993). In contrast, the minor group of rhino-
viruses uses the uppermost rim of the north canyon to
interact with LDL receptors (Hewat et al., 2000). It has been
suggested that the mechanism of action of the WIN com-
pounds is abrogation of receptor interaction in the case of
the major group of rhinoviruses (Pevear et al., 1989). How-
ever, it seems likely that these compounds have the primary
effect of stabilizing the capsids of all rhinoviruses and, in
the case of the major group, this stabilization of the canyon
region affects the virus/receptor affinity. Since the receptor
for the minor group is well outside the canyon region
(Hewat et al., 2000), it follows that receptor–virus interac-
tions are unaffected by the drugs. As has been previously
suggested (Lewis et al., 1998), it seems likely that drug-
mediated stabilization prevents capsid breathing that is in
turn crucial for uncoating. In this way, all HRV’s are in-
hibited by WIN compounds and their derivatives.
The dansylaziridine compounds differ from the WIN
compounds in that they offer a “two-prong” attack on the
viruses. In previous studies, it was shown that these com-
pounds take advantage of capsid dynamics to penetrate the
protein shell and covalently modify the RNA genome (Broo
et al., 2001). The results presented here demonstrate that
these alkylating agents have a second effect in that the
modification of the RNA causes a marked destabilization of
the capsid. Such destabilization would likely interfere with
the efficacy of viral transmission and makes these com-
pounds even more efficacious.
These studies also demonstrate how the combination of
limited proteolysis and isotope labeling can be used to
qualitatively and quantitatively ascertain the modes of in-
activation. Traditionally, the efficacies of antiviral agents
are often measured by plaque assays and lethal dosing
(LD50) experiments and often do not reveal the mode of
inactivation. In this case, WIN and alkylating agents both
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effectively neutralize infectivity but have completely oppo-
site modes of action. The techniques described here offer an
efficient means to discern these differences. Furthermore,
these results show the key role capsid dynamics can play in
virus inactivation and may be further exploited in antiviral
drug development. The quantitative nature of these tech-
niques will be useful to assess the relative effectiveness of
antiviral agents. In addition, these methods can be used to
determine the number of antiviral molecules required to
neutralize the virion. Such studies on WIN compounds have
been impossible using plaque assays since the concentration
of drugs in solution is hard to ascertain because these
hydrophobic compounds partition into cell membranes.
The results of the Fab17-mediated stabilization suggest
that canyon motion is part of the capsid breathing process.
Fab17 and other NIm-IA antibodies penetrate into the can-
yon region and stabilize the virus against pH and thermal
denaturation (Che et al., 1998; Smith et al., 1996). What is
shown here is that Fab17, by wedging into the canyon
region but not inducing any conformational changes (Smith
et al., 1996), blocks breathing in the same way as the
antiviral compounds. The effects of the antiviral compounds
could be relatively diffuse—affecting a number of confor-
mational changes associated with uncoating. However, the
antibodies are clearly filling the canyon without inducing
conformational changes. This all implies that breathing re-
quires conformational flexing of the canyon region and this
process is being blocked by the extensive antibody/canyon
interactions with the north wall, south wall, and base of the
canyon. The WIN drugs accomplish the same effect by
binding under the canyon floor. Interestingly, the receptor
ICAM-I binding region overlaps with the antibody contact
region on the south wall, causing the opposite effect com-
pared to the antibody.
The effects of the drug-binding cavity mutations on cap-
sid breathing are entirely consistent with these hypotheses.
The results shown here demonstrate that filling this cavity
with nonpolar elements mimics, to a degree, the effects of
WIN drugs. The fact that these mutations do not affect viral
infectivity (U. Katpally and T.J. Smith, unpublished data);
however, makes it important to note that these breathing
measurements are performed in the absence of receptor.
With receptor bound, the differences between WIN and
pocket mutations are expected to be more pronounced.
Another possible conclusion from these results is that capsid
breathing may be linked to conformational changes in the
canyon and this motion facilitates improved interactions
with the receptor. In this way, the WIN drugs can indirectly
affect the binding of ICAM-1 to the major group of rhino-
viruses by disrupting capsid breathing. The fact that filling
the drug binding cavity with hydrophobic residues through
mutagenesis causes stabilization similar to that of WIN
compounds suggests that all of these effects are driven by
changes in entropy as previously suggested for HRV14
(Phelps and Post, 1995; Smith, 1989) and experimentally
demonstrated in the case of poliovirus (Tsang et al., 2000).
Materials and methods
HRV14 mutagenesis
HRV14 cDNA that produces infectious RNA (Wang et
al., 1998) was used as a template for mutagenesis by the
PCR overlap method. The two mutation sites, V1188 and
C1199, are in the cDNA region, enclosed by the two unique
restriction sites DraIII and AvrII. Two oligos were synthe-
sized, one in 5-3 orientation, covering the DraIII site, and
one in 3-5 orientation, covering the AvrII site. For each
mutation, fragments of two portions of the cDNA were
made by PCR using one primer for the end of the DraIII and
AvrII region and the other primer containing the mutation.
These fragments were then used as primers for subsequent
PCR reactions to make the full-length DraIII/AvrII frag-
ment. For the double mutation, the V1188M PCR product
was used as a template for amplification with the C1199W
primers. These fragments were inserted into the HRV14
cDNA using the DraIII and AvrII restriction sites. The
mutated cDNA was sequenced to verify the mutations.
Transfection and amplification
The DEAE-dextran transfection procedure was described
elsewhere (Wang et al., 1998). RNA transcripts from the
full-length mutated HRV14 cDNA were made using in vitro
transcription. The RNA transcripts were diluted in HEPES-
buffered saline containing 200 g DEAE-dextran/ml. The
dilutions were added to HeLa cell monolayers and incu-
bated at room temperature for 60 min. The cells were
washed to remove DEAE-dextran and supplemented with 4
ml of AH medium in a liquid overlay method. The plates
were incubated for 48 h before the cells were scraped and
the virus particles were released with repeated freezing and
thawing. Plaque assays were performed to check for parti-
cles. Virus titer amplification was accomplished using
monolayers of HeLa cells on T75 flasks and later on roller
bottles until the titer was 107 PFU/ml. Virus was purified
and RNA was extracted as described elsewhere (Erickson et
al., 1983; Wang et al., 1998). cDNA corresponding to the
structural proteins, VP1–VP4, was made by RT-PCR and
sequenced. Even after several passages, RT-PCR and se-
quencing analysis of the entire capsid region showed that
the mutations V1188M and C1199W were unaltered and no
second site mutations were observed (data not shown).
Virus purification
Human rhinovirus 14 was produced using previously
described protocols (Erickson et al., 1983). In brief, HeLa
cells were infected with HRV14 at a multiplicity of infec-
tion of 10. After incubating the infected cells at 34.5°C for
10.5 h, the virus was purified from lysed cells treated with
N-lauryl-sarcosine to solubilize cellular debris. However,
unlike the previously described protocol, the lysed cellular
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material was not treated with trypsin since even this brief
treatment resulted in cleavage of VP1 and VP4 (data not
shown). Virus particles were pelleted by ultra centrifugation
at a maximum centrifugal force of 278,434 g for 2 h and
purified with a 7.5–45% sucrose gradient spun at a maxi-
mum centrifugal force of 2  105 g for 1.5 h. The virus
bands were collected and dialyzed against 10 mM Tris
buffer, pH 7.2. HRV14 concentration was determined spec-
trophotometrically using an extinction coefficient of 7.7
ml/mg · cm at 260 nm and stored at 4°C.
Fab 17-IA preparation
Monoclonal antibodies (Mabs) 17-IA were produced as
previously described (Smith et al., 1993) using the Cellmax
Quad 4 cell-culture system (Cellco Corp., Germantown,
MD) and purified with a protein G affinity column.
Fab17-IA fragments were made by papain cleavage using
an enzyme-to-antibody ratio of 1:100 (w/w) and incubated
at 37°C for 10 h in the presence of 25 mM -mercaptoetha-
nol. The digested fragments were dialyzed against 10 mM
Tris–HCL, pH 7.5, and purified by ion exchange on a FPLC
system (Pharmacia, Piscataway, NJ).
Mass spectrometry
Qualitative mass spectrometry experiments were con-
ducted using a PerSeptive Biosystems (Framingham, MA)
Voyager-DE.STR MALDI time-of-flight reflectron mass
spectrometer equipped with a nitrogen laser. MALDI gen-
erated ions were accelerated into the time-of-flight mass
analyzer by a 20-kV pulse after a 200-ns delayed extraction
period. Detector voltages were turned on after ions greater
than m/z 600 had passed the detector (with a “low mass
gate”) to improve detection sensitivity for the ions of inter-
est. MALDI analyses utilized 3,5-hydroxycinnamic acid
(Sigma-Aldrich, St. Louis, MO) as the matrix dissolved in a
70% acetonitrile/30% water (0.1% trifluoroacetic acid) so-
lution. Sample volumes of 0.5 L were applied to the
MALDI plate followed by 0.5 L of the matrix solution and
allowed to dry. All MALDI spectra were generated from an
average of 128 laser pulses.
Quantitative virus-drug stability studies were performed
using nano-LC electrospray on a LCQ ion-trap mass spec-
trometer (ThermoFinnigan Inc., San Jose, CA). The elec-
trospray and the internal capillary line/skimmer potentials
were set at 1800 and 57 V, respectively, with a capillary line
temperature of 150°C. The injected ions were trapped and
scanned between m/z 400 and 1800. For ion detection, the
conversion dynode and electron multiplier were set at 15
and 1.05 kV, respectively. LC capillaries (100 m i.d.)
were drawn to approximately 5 mm i.d. tips using a laser-
based micropipette/fiber puller (Sutter Instrument Co, No-
vato, CA) and packed with 5 m C18 stationary phase
particles using a high-pressure bomb built in-house. Sam-
ples volumes of 5–10 l were loaded directly onto the
capillary columns using the same high-pressure bomb.
Chromatographic separations were performed by splitting
the solvent flow from an Agilent 1100 binary HPLC pump
to yield a final LC flow rate of 0.3–0.56 l/min. Peptides
were eluted with a gradient of 0 to 15% acetonitrile in 0.1%
acetic acid for 1 min followed by a gradient of 15 to 100%
with 80% acetonitrile in 0.1% acetic acid for 55 min.
Limited proteolytic digestions for isotopic labeling stud-
ies using pleconaril and dansylaziridine were performed at
37°C. Modified trypsin (Promega, Madison, WI) and Glu-C
(Roche Diagnostics, Indianapolis, IN) digests were per-
formed in 10 mM ammonium bicarbonate (pH 7.8) and 10
mM ammonium acetate (pH 4.3), respectively. Enzyme-to-
virus ratios of 1:500 and 1:1000 (w/w) were used for these
limited proteolysis experiments. Isotope-labeling was
achieved by exchanging the aqueous buffer with O18–water
(Isotec Inc., Miamisburg, OH) buffer. Purified picovir (ple-
conaril) was supplied by Dan Pevear (Viropharma Inc.,
King of Prussia, PA), whereas dansylaziridine was synthe-
sized and purified as previously described (Broo et al.,
2001).
Wild-type HRV14 versus mutant HRV14
For studies comparing HRV14 and the mutant form of
HRV14, virus samples were prepared to a final concentra-
tion of 1.0 mg/ml in 10 mM Tris buffer at pH 7.6. Modified
trypsin (Promega) was dissolved in water and digests were
performed at 25 or 37°C using a 1:100 enzyme-to-virus
ratio. In samples where WIN 52084 was used, a final con-
centration of 10 g/ml was added 10 min prior to the
addition of trypsin. Where dansylaziridine was used, a 10
mM stock solution in 50% acetonitrile was added to sam-
ples for a final concentration of 1 mM. For control samples,
a final concentration of 5% acetonitrile or 0.1% DMSO
were added. Reaction volume was 10 l and 0.75 l was
plated directly on the MALDI analysis plate. Subsequently,
0.75 l of matrix [3,5-dimethoxy-4-hydroxy cinnamic acid]
(Aldrich) in a saturated solution of acetonitrile/water (50:
50)/0.25% trifluoracetic acid was added to the plate.
Mass spectrometry experiments for these studies were
conducted using an Applied Biosystems (Framingham,
MA) Voyager-DESTR MALDI time-of-flight reflectron
mass spectrometer. MALDI-generated ions were acceler-
ated into the time-of-flight mass analyzer by a 20-kV pulse
after a 100-ns delayed extraction period. Detector voltages
were turned on after ions greater than m/z 700 had passed
the detector (with a low mass gate) to improve detection
sensitivity for the ions of interest. Figs. 3B and C were
generated from individual MALDI spectra, such as in Fig.
3A, by comparing the peak height of VP4 between time
points of each treatment. For each treatment, the VP4 peak
at zero time was set to 100% and the percentage of VP4
from the remaining time points was calculated based on this
value. In cases where the value of VP4 exceeded the control
value, this amount was set to 100% for simplicity. Experi-
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ments were repeated a minimum of three times and an
average of two to three experiments were used to obtain the
resulting graphs and error bars.
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